Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Other Accumulated Expenses (2023 - 2025)

Historic Other Accumulated Expenses for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $895000.0.

  • Artiva Biotherapeutics' Other Accumulated Expenses fell 5964.83% to $895000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $895000.0, marking a year-over-year decrease of 5964.83%. This contributed to the annual value of $1.5 million for FY2024, which is 4854.95% down from last year.
  • Per Artiva Biotherapeutics' latest filing, its Other Accumulated Expenses stood at $895000.0 for Q3 2025, which was down 5964.83% from $997000.0 recorded in Q2 2025.
  • Artiva Biotherapeutics' 5-year Other Accumulated Expenses high stood at $2.9 million for Q4 2023, and its period low was $895000.0 during Q3 2025.
  • Its 3-year average for Other Accumulated Expenses is $1.6 million, with a median of $1.2 million in 2024.
  • As far as peak fluctuations go, Artiva Biotherapeutics' Other Accumulated Expenses tumbled by 4854.95% in 2024, and later tumbled by 5964.83% in 2025.
  • Artiva Biotherapeutics' Other Accumulated Expenses (Quarter) stood at $2.9 million in 2023, then crashed by 48.55% to $1.5 million in 2024, then plummeted by 39.2% to $895000.0 in 2025.
  • Its last three reported values are $895000.0 in Q3 2025, $997000.0 for Q2 2025, and $1.0 million during Q1 2025.